{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:31:51Z","timestamp":1787963511239,"version":"build-2784847793"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T00:00:00Z","timestamp":1557100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ijantimicag.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T12:51:49Z","timestamp":1557319909000},"page":"255-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of methods to analyse susceptibility of German MDR\/XDR Pseudomonas aeruginosa to ceftazidime\/avibactam"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-9290","authenticated-orcid":false,"given":"Frieder","family":"Schaumburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Bletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Mellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6391-1341","authenticated-orcid":false,"given":"Karsten","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny A.","family":"Idelevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0001","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-018-0629-6","article-title":"Multidrug-resistant Pseudomonas infections: hard to treat, but hope on the horizon?","volume":"20","author":"Nguyen","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0003","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0004","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0005","first-page":"1311","article-title":"[Hygiene measures for infection or colonization with multidrug-resistant Gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI)]","volume":"55","year":"2012","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0006","series-title":"Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases","article-title":"Clinical laboratory testing and in vitro diagnostic test systems \u2013 susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices","year":"2006"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0007","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0008","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0009","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkx253","article-title":"Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods","volume":"72","author":"Schaumburg","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0010","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1128\/JCM.00790-16","article-title":"Real-time genome sequencing of resistant bacteria provides precision infection control in an institutional setting","volume":"54","author":"Mellmann","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0011","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/jac\/dks261","article-title":"Identification of acquired antimicrobial resistance genes","volume":"67","author":"Zankari","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0012","doi-asserted-by":"crossref","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","article-title":"Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases","volume":"288","author":"Ehmann","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0013","series-title":"Part 2: Evaluation of performance of antimicrobial susceptibility test devices","article-title":"Clinical laboratory testing and in vitro diagnostic test systems \u2013 susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test device","year":"2007"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0014","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1128\/AAC.48.6.2043-2048.2004","article-title":"Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa","volume":"48","author":"Girlich","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0015","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/jac\/dky279","article-title":"Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015\u201317)","volume":"73","author":"Sader","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0016","doi-asserted-by":"crossref","first-page":"e00528-18","DOI":"10.1128\/JCM.00528-18","article-title":"Performance of the Etest for susceptibility testing of Enterobacterales (Enterobacteriaceae) and Pseudomonas aeruginosa toward ceftazidime-avibactam","volume":"56","author":"Kresken","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0017","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/jac\/dky483","article-title":"Performance of ceftazidime\/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms","volume":"74","author":"Wenzler","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0018","doi-asserted-by":"crossref","first-page":"e01093-17","DOI":"10.1128\/JCM.01093-17","article-title":"Verification of ceftazidime-avibactam and ceftolozane-tazobactam susceptibility testing methods against carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa","volume":"56","author":"Shields","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.drup.2015.08.002","article-title":"The increasing threat of Pseudomonas aeruginosa high-risk clones","volume":"21\u201322","author":"Oliver","year":"2015","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ijantimicag.2018.07.027","article-title":"Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis","volume":"52","author":"Chalhoub","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.05.001_bib0021","doi-asserted-by":"crossref","first-page":"e01379-18","DOI":"10.1128\/AAC.01379-18","article-title":"Mutation-driven evolution of Pseudomonas aeruginosa in the presence of either ceftazidime or ceftazidime-avibactam","volume":"62","author":"Sanz-Garcia","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:35:00Z","timestamp":1760376900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0924857919301086"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.05.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of methods to analyse susceptibility of German MDR\/XDR Pseudomonas aeruginosa to ceftazidime\/avibactam","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}